Xeltis’ first commercial deal and its first funding from an Asian company
Reduces the risk of death at 5 and 10 years by 26% and 23% respectively.
The MAFTEST®, is intended to detect in the tumor the amplification involving the MAF gene region in order to determine the risk in early-stage breast cancer patients.
Study shows ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury in rodents
Aura expects to initiate the trial in the second half of 2022, with initial Phase 1 data expected in 2023.
In this Retrospective Matched Case Control Study, Belzupacap Sarotalocan Achieved Statistically Significant Vision Preservation
We remain on track with our Phase 2 SC study and we plan to finalize a decision on the route of administration and initiate our pivotal program before the end of the year.
James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies
This addition will strengthen the Ysios Capital team by incorporating an expert in legal matters.
Subscribe to our weekly newsletter for the latest updates on life sciences investments.